Haemonetics (NYSE:HAE) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Haemonetics (NYSE:HAE) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01), Zacks reports. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics updated its FY 2025 guidance to 4.500-4.700 EPS.

Haemonetics Stock Down 3.0 %

Shares of HAE stock traded down $1.91 on Friday, hitting $61.08. The stock had a trading volume of 933,742 shares, compared to its average volume of 873,039. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of 25.33, a P/E/G ratio of 1.07 and a beta of 0.39. The stock’s 50 day moving average is $76.94 and its 200-day moving average is $78.62. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics has a 52-week low of $60.74 and a 52-week high of $97.97.

Wall Street Analyst Weigh In

Several research firms have weighed in on HAE. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a report on Friday, November 8th. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target for the company. Barrington Research dropped their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $95.00 to $68.00 in a research report on Friday. Finally, Needham & Company LLC dropped their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $102.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.